Substance / Medication

Sunitinib

Overview

Active Ingredient
sunitinib
RxNorm CUI
357977

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Factors Affecting Pharmacokinetics of Sunitinib and Its Metabolite, SU12662: A Systematic Review of Population Pharmacokinetic Studies.
Shah Heta N, Veerabhadrappa Jayashree, Damre Anagha et al. · Eur J Drug Metab Pharmacokinet · 2025
PMID: 41023290Meta-Analysis
Comparison of Anti-Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis.
Maiorano Brigida Anna, Ciardiello Davide, Maiello Evaristo et al. · JAMA Netw Open · 2023
PMID: 37200035Meta-AnalysisFull text (PMC)
Hematologic toxicities of sunitinib in patients with gastrointestinal stromal tumors: a systematic review and meta-analysis.
Jiang Xuehui, Xiong Fangfang, Fu Qun et al. · Int J Colorectal Dis · 2022
PMID: 35780257Meta-Analysis
Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors.
Wang Erjian, DuBois Steven G, Wetmore Cynthia et al. · Eur J Drug Metab Pharmacokinet · 2021
PMID: 33852135Meta-AnalysisFull text (PMC)
Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis.
Liu Xiu-Lan, Xue Hui-Ying, Chu Qian et al. · Medicine (Baltimore) · 2020
PMID: 32221075Meta-AnalysisFull text (PMC)
Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis.
Kang Hee Jung, Lee Soohyeon · Yonsei Med J · 2020
PMID: 32975057Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sunitinib (substance)
SNOMED CT
421192001
UMLS CUI
C1176020
RxNorm CUI
357977

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.